A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma

Leuk Lymphoma. 2023 Mar;64(3):722-724. doi: 10.1080/10428194.2022.2045598. Epub 2022 Mar 9.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Humans
  • Lymphoma, Mantle-Cell* / drug therapy
  • Lymphoma, Mantle-Cell* / pathology
  • Neoplasm Recurrence, Local / drug therapy
  • Piperidines

Substances

  • ibrutinib
  • obinutuzumab
  • Piperidines